Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Candesartan cilexetil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Takeda
- 01 Feb 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 01 Feb 2011 Actual initiation date Jul 2007 and actual end date Jul 2008 are addedd as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed to completed. Azilsartan has moved into phase III development in Japan, according to a Takeda media release.